Selvigaltin (GB1211), an orally obtainable small molecule galectin-three inhibitor developed being a therapy for liver fibrosis and cirrhosis, was evaluated to evaluate the outcome of hepatic impairment on its pharmacokinetics and security to handle regulatory requirements. Inhibition of galectin-3 with GB1211 was not connected with any procedure- or dose-related traits https://davidg443rdn6.madmouseblog.com/profile